GSK's stock (NYSE: GSK) plunged over 6% after the US CDC restricted RSV vaccine use, recommending it only for high-risk individuals aged 60-74. The change impacts GSK's Arexvy vaccine, crucial for revenue amidst looming patent expirations. Analyst forecasts may be revised downwards.
